Neosense Technologies
Continuous oxygen monitoring systems for intensive care.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
SEK2.8m | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 92 % | - | - | - | 2559 % | 9 % | (6 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3638 %) | - | - | (1277 %) | (47 %) | (39 %) | (32 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Neosense Technologies AB is a Swedish medical technology company that develops advanced continuous oxygen monitoring systems for intensive care units. Founded in 2014 by Kenneth Danehorn and Nils Holmström as a spin-off from the KTH Royal Institute of Technology in Stockholm, the firm focuses on improving patient safety and enabling more precise clinical decisions. The co-founders brought extensive experience to the venture; Danehorn has over 25 years in the medtech business, while Holmström has over 30 years in R&D within the medical device industry. The core technology is a proprietary, first-in-class sensor for real-time measurement of blood oxygen tension.
The primary application for Neosense's technology is in neonatal care, specifically for extremely preterm infants who require supplemental oxygen. For these patients, maintaining blood oxygenation within a very narrow range is critical, as both excessive and insufficient levels can lead to severe complications, including eye damage, organ injury, or mortality. The company's system is designed to provide the real-time data needed to manage oxygen therapy with high precision, addressing the shortcomings of existing monitoring methods. By enabling this level of control, Neosense aims to reduce permanent complications and mortality for critically ill newborns.
The business model is focused on providing these advanced monitoring solutions to healthcare providers globally. Neosense Technologies has raised a total of $122K in seed funding over two rounds, with investors including Almi Invest, KTH Holding, and Keiretsu Forum Nordics. The capital was intended to support clinical trials and the production of a CE-marked product for commercialization in the European healthcare market.
Keywords: continuous oxygen monitoring, neonatal intensive care, blood oxygen sensor, medtech, real-time monitoring, critical care devices, patient safety, preterm infants, blood gas monitoring, oxygen therapy, clinical decision support, medical devices, neonatal care, KTH spin-off, healthcare technology, vital signs monitoring